Articles On Prescient Therapeutics (ASX:PTX)
Title | Source | Codes | Date |
---|---|---|---|
Prescient unveils latest big hitter CellPryme-A at prestigious Boston CAR-TCR meeting
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR Summit in Boston, the world’s pre-eminent forum in the CAR and TCR fields of cellular immunotherapy. Clinical stage oncolog... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) unveils new treatment to boost CAR-T performance
Prescient Therapeutics (PTX) unveils a novel adjuvant for enhancing cellular immunotherapyCellPryme-A was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CA... |
themarketherald.com.au | PTX | 1 year ago |
Prescient Therapeutics debuts CellPryme-A at world’s largest CAR-TCR meeting in Boston
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination with cellular immunotherapy such as CAR-T. CellPryme-... |
SmallCaps | PTX | 1 year ago |
Prescient joins up with renowned US cancer centre in fight against blood cancer
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has signe... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics enters strategic collaboration with largest cancer centre in US
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US to create “best-in-class” adaptable CAR-T cell therapies to treat blood cancers. Under the collaboration, Prescient’s next generati... |
SmallCaps | PTX | 1 year ago |
Prescient Therapeutics enters strategic collaboration with renowned US cancer centre
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with a renowned US cancer centre to create “best-in-class” adaptable CAR-T cell therapies to treat blood cancers. Under the collaboration, Prescient’s next generation C... |
SmallCaps | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) partners with MD Anderson Cancer Center
Prescient Therapeutics (PTX) partners with the largest cancer centre in the US to create best-in-class, adaptable CAR-T cell therapies to treat certain cancer typesThe company will collaborate with the University of Texas MD Anderson Cancer... |
themarketherald.com.au | PTX | 1 year ago |
Excitement builds as Prescient achieves key milestones in personalised cancer treatment
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and its leader believes its recent momentum is just the beginning. You can sense the excitement in the voice of Prescient Therapeutics (AS... |
Stockhead | PTX | 1 year ago |
90 Seconds With… Steven Yatomi-Clarke, Prescient Therapeutics (ASX:PTX)
Got 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke tell us about their company news. Prescient Therapeutics (ASX:PTX) develop novel, personalised therapies for a range of cancers. The company has a broad pipeli... |
Stockhead | PTX | 1 year ago |
Prescient launches capital raise to progress pipeline of cancer therapies
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies with capital raise. The company is looking to raise $8 million in funds via a Share Purchase Plan at $0.175 per share to mai... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics to progress innovative pipeline of cancer treatments with capital raise
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum in developing its pipeline of innovative cancer and cell therapies and move towards first-in-human clinical studies. Prescient ha... |
SmallCaps | PTX | 1 year ago |
Prescient Therapeutics launches share purchase plan to raise $8 million
Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan (SPP) targeting to raise $8 million. |
BiotechDispatch | PTX | 1 year ago |
Why is the Prescient share price diving 12% on Wednesday?
The Prescient Therapeutics Ltd (ASX: PTX) share price is plunging during late afternoon trade on Wednesday. This follows the companyâs latest announcement regarding the launch of a share purchase plan (SPP). At the time of writing, share... |
Motley Fool | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) to raise $8m for cancer treatment therapies
Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies The company will also use the funds to progress its cell therapies to first-in-human... |
themarketherald.com.au | PTX | 1 year ago |
Prescient joins world-leader in cell and gene therapy to accelerate OmniCAR platform
Prescient has joined forces with Thermo Fisher Scientific for a research program aiming to advance development of its next-generation cellular therapies. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has signed an agree... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) signs deal with Thermo Fisher for OmniCAR development
Prescient Therapeutics (PTX) signs a deal with Thermo Fisher Scientific to accelerate the development of its OmniCar platform The work program will aim to develop the next generation OmniCAR cells that can be produced with greater efficien... |
themarketherald.com.au | PTX | 1 year ago |
Prescient Therapeutics signs deal with Thermo Fisher Scientific to accelerate development of OmniCAR cell therapy platform
Australian biotech Prescient Therapeutics (ASX: PTX) has signed an agreement with US-based pharmaceutical services solutions company Thermo Fisher Scientific to accelerate development and commercialisation of a scalable version of its OmniC... |
SmallCaps | PTX | 1 year ago |
Prescient secures OmniCAR cell lines for upcoming clinical trials
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical Research Institute in Brisbane to advance clinical trials of its OmniCAR cell lines. Clinical stage oncology company Prescient Therapeuti... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics signs deal with Q-Gen to enable OmniCAR clinical trials
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer Q-Gen Cell Therapeutics for the manufacture of its OmniCAR cell lines for upcoming clinical trials.... |
SmallCaps | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) strikes a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials The treatment will be studied against a range of cancers, but it is lik... |
themarketherald.com.au | PTX | 1 year ago |
Webinar Recap – HPC, PTX, AR9 & MEK
ShareCafeWebinar Recap – HPC, PTX, AR9 & MEK Catch up on the full webinar presentations from The Hydration Pharmaceutical Company (ASX HPC), Prescient Therapeutics (ASX: PTX), archTIS (ASX: AR9) & Meeka Metals (ASX: MEK) Webinar Re... |
ShareCafe | PTX | 1 year ago |
Prescient Therapeutics (ASX: PTX) – Webinar Presentation
ShareCafePrescient Therapeutics (ASX: PTX) – Webinar Presentation Steven Yatomi-Clarke – CEO & MD – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers. Prescient Therapeutics (ASX: PTX)... |
ShareCafe | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) advances clinical programs in June quarter
Oncology company Prescient Therapeutics (PTX) focused on advancing its targeted and cell therapies during the June quarter Promising trial data led the company to expand its PTX-100 therapy to treat T-cell lymphomas with recruitment expect... |
themarketherald.com.au | PTX | 1 year ago |
Steven Yatomi-Clarke from Prescient Therapeutics (PTX) - Switzer Small and Micro Cap Investor Strategy Day 2022
Steven Yatomi-Clarke of Prescient Therapeutics speaks at the Switzer Small and Micro Cap Investor Strategy Day 2022. |
Switzer | PTX | 1 year ago |
Prescient first in class cancer drug PTX-100 granted Orphan Drug status by the US FDA
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market exclusivity and other commercial benefits in blood cancer PTCL. Clinical stage oncology company Prescient Therapeutics (ASX: PTX) announced that the US FDA h... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) receives orphan drug designation for PTX-100
Prescient Therapeutics (PTX) receives orphan drug designation for its PTX-100 product for the treatment of peripheral T-cell lymphomas (PTCL) Orphan drug designation is given to drugs that are intended to treat rare diseases, and it gives... |
themarketherald.com.au | PTX | 1 year ago |
Top 10 at 10: Which ASX stocks are cruising and snoozing today?
Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | PTX | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | PTX | 1 year ago |
ASX Health Stocks: US patent another Prescient win for booming Aussie biotechs
Prescient gets US patent approval Genetic Technologies expands EasyDNA into India and Europe Imricor submits cardiac ablation catheter for EU market Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has been granted a US p... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform
Prescient Therapeutics (PTX) is granted a key US patent for its OmniCAR universal immune receptor (UIR) platform The new patent protects Prescient’s two-part covalent binding system known as SpyTag and SpyCatcher, which forms a key compone... |
themarketherald.com.au | PTX | 1 year ago |
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy sector, unveiling its latest platform to advance CAR-T therapy globally. Leading ASX oncology company developing personalised therapies... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance cell therapies. Developed by Prescien... |
SmallCaps | PTX | 1 year ago |
Prescient expands PTX-200 AML cohort following additional complete remission
Prescient Therapeutics (ASX:PTX) has announced the expansion of its Phase 1b clinical study of PTX-200 and cytarabine in patients with relapsed and refractory acute myeloid leukemia. |
BiotechDispatch | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) expands study after fourth remission
Prescient Therapeutics (PTX) expands its clinical study of patients with relapsed and refractory acute myeloid leukaemia (AML) The addition to the company’s Phase 1b clinical study of PTX-200 and cytarabine follows another complete patien... |
themarketherald.com.au | PTX | 1 year ago |
Closing Bell: Between rocks and a hard place (to get COVID), small caps crash and stimmy hopes dash on China lockdowns
XEC falls hard on Monday XOJ closes 1.2% lower Seafarms Group (ASX:SFG) recovers Friday losses Australian markets fell and fell hard on Monday. The benchmark ASX200 is nudging two month lows, while the Greenback’s near 20-year high has... |
Stockhead | PTX | 1 year ago |
Meet the pain: Eddy quaffed all these small cap quarterlies and we saved you the best bits
Quarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin to meeting your boyfriend’s parents, it always reveals a hell of a lot about the boy, inside the man. And so, Stockhead’s sublimely single b... |
Stockhead | PTX | 1 year ago |
Fighting Back: 3 ASX cancer stocks giving hope in a leading cause of death
Prescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to activate the immune systems of cancer suffers to fight disease Rhythm Bioscience revolutionising the detection of bowel cancer According to th... |
Stockhead | PTX | 1 year ago |
Prescient Therapeutics (ASX:PTX) seeking patients for expanded clinical study of PTX-100 cancer treatment
Prescient Therapeutics (PTX) opens patient enrolments for an expanded phase 1B trial of its PTX-100 therapy to treat T-cell lymphomas, a group of aggressive and rare blood cancers The company is looking to recruit eight to 12 patients suff... |
themarketherald.com.au | PTX | 2 years ago |
Prescient Therapeutics begins recruiting for expanded trial of PTX-100 in blood cancer
Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in treating aggressive rare blood cancers where the company says there is a “significant unmet clinical need”. The company announ... |
SmallCaps | PTX | 2 years ago |
Prescient Therapeutics half-year update shows why it’s one of the most exciting cancer research companies on the ASX
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and its world-leading OmniCAR research platform. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) updated the market with its half-yea... |
Stockhead | PTX | 2 years ago |
New Portfolio Addition: Arovella Therapeutics
Disclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 13,631,579 ALA shares. S3 Consortium Pty Ltd has been engaged by ALA to share our commentary on the progress of our in... |
FinFeed | PTX | 2 years ago |
New data bolsters Prescient Therapeutics’ focus on next generation CAR-T cell therapy for cancers
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use of next generation cell therapy platform OmniCAR, which harnesses a patient’s own immune system to fight c... |
SmallCaps | PTX | 2 years ago |
Prescient Therapeutics in strong cash position to support OmniCAR clinical studies
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a cash balance of $14.77 million, placing it in a strong financial position to support its multiple cancer therapy progra... |
SmallCaps | PTX | 2 years ago |
Prescient is well funded as it looks to bring its novel OmniCAR T-cell therapy into clinical trials
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR therapy into the clinic as it looks to unlock shareholder value. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) ended the quarter in a str... |
Stockhead | PTX | 2 years ago |
Here’s what CEOs are hoping to change with their New Year’s resolutions for 2022
It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan... |
Stockhead | PTX | 2 years ago |
Waiting for 2022? Here’s a bunch of books CEOs are reading during the holiday break
It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan... |
Stockhead | PTX | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | PTX | 2 years ago |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19 ravaged the world. Nasdaq-listed BioNTech, which... |
Stockhead | PTX | 2 years ago |
CEOs look ahead to three things they’re hoping for in 2022
It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan... |
Stockhead | PTX | 2 years ago |
CEOs look back and share their company highlights from 2021
It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up. But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chan... |
Stockhead | PTX | 2 years ago |